The Role of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Assessing the Response to Neoadjuvant Treatment in Patients with Osteosarcoma

Table 1

Prospective studies.

Authors (reference)	Journal/year	Patients; (OS)	Gender; (% male)	Age; (range)	Quantification indexes
Jones et al. [17]	J Nucl Med/1996	9 (3)	67	15–65	SUV, TBR
Schulte et al. [18]	J Nucl Med/1999	27 (27)	63	5–33	%TBR
Ye et al. [19]	Ann Nucl Med/2008	15 (15)	60	7–33	SUV-ratio, %TBR
Sato et al. [20]	Clin Exp Metastasis/2008	13 (13)	77	11–54	SUV
Benz et al. [21]	J Nucl Med/2008	33 (8)	49	19–86	SUV, TBR, SUV-ratio, %TBR
Benz et al. [22]	Sarcoma/2010	12 (6)	42	18–61	SUV, SUV-ratio
Denecke et al. [23]	Eur J Nucl Med Mol Imaging/2010	27 (11)	56	3–18	SUV, SUV-ratio
Tateishi et al. [24]	Clin Nucl Med/2011	42 (NR)	62	32–72	SUV
Bajpai et al. [25]	J Pediatr Hematol Oncol/2011	31 (31)	81	5–66	SUV, SUV-ratio, MB
Im et al. [26]	Eur J Nucl Med Mol Imaging/2012	20 (20)	50	10–25	SUV, MTV, TLG, SUV-ratio, MTV-ratio, %TLG

SUV: standardized uptake value; TBR: tumour-to-background ratio; MB: metabolic burden; TLG: total lesion glycolysis; %TBR: percent change in TBR (baseline to posttherapy); %TLG: percent change in TLG (baseline to posttherapy); NR: not reported.